Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer
…, WA Weber, M Schwaiger, K Knorr, M Eiber - European urology, 2019 - Elsevier
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is increasingly
being used in metastatic castration-resistant prostate cancer (mCRPC). The objective of …
being used in metastatic castration-resistant prostate cancer (mCRPC). The objective of …
Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial
WP Fendler, J Calais, M Eiber, RR Flavell… - JAMA …, 2019 - jamanetwork.com
Importance In retrospective studies, 68 Ga-PSMA-11 positron emission tomographic (PET)
imaging improves detection of biochemically recurrent prostate cancer compared with …
imaging improves detection of biochemically recurrent prostate cancer compared with …
Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer
…, N Tamaki, M Schwaiger, T Maurer, M Eiber - European journal of …, 2016 - Springer
Purpose The aim of our study was to compare the diagnostic performance of 68 Ga-PSMA
PET and 99m Tc bone scintigraphy (BS) for the detection of bone metastases in prostate …
PET and 99m Tc bone scintigraphy (BS) for the detection of bone metastases in prostate …
[HTML][HTML] Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)
Context Prostate-specific membrane antigen (PSMA) targeting positron emission tomography
(PET) is emerging to become a reference imaging tool for the staging and restaging of …
(PET) is emerging to become a reference imaging tool for the staging and restaging of …
Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration …
…, M Schwaiger, R Tauber, M Eiber - The Journal of …, 2016 - auajournals.org
Purpose : We report our initial clinical experience with β -emitting 177 Lu-PSMA-I&T ( 177
Lu labeled prostate specific membrane antigen ligand for imaging and therapy) for systemic …
Lu labeled prostate specific membrane antigen ligand for imaging and therapy) for systemic …
Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions
…, M Schwaiger, S Ziegler, M Eiber - Journal of Nuclear …, 2017 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy is increasingly
used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed …
used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed …
Impact of 68Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial
…, J Ferdinandus, J Czernin, M Eiber… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) ligand PET induces management changes in
patients with prostate cancer. We aim to better characterize the impact of 68 Ga-PSMA-11 …
patients with prostate cancer. We aim to better characterize the impact of 68 Ga-PSMA-11 …
Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA
…, WA Weber, C D'Alessandria, A Morgenstern, M Eiber - European urology, 2021 - Elsevier
Background Beta-emitting Lu-177-labeled prostate-specific membrane antigen (PSMA)
radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate cancer (…
radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate cancer (…
Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT
M Eiber, K Herrmann, J Calais… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA)–ligand PET imaging provides unprecedented
accuracy for whole-body staging of prostate cancer. As PSMA-ligand PET/CT is increasingly …
accuracy for whole-body staging of prostate cancer. As PSMA-ligand PET/CT is increasingly …
Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging
M Eiber, AJ Beer, K Holzapfel, R Tauber… - Investigative …, 2010 - journals.lww.com
Objectives: In this retrospective feasibility study diffusion-weighted magnetic resonance
imaging (DWI) was evaluated as a potential tool for characterization of pelvic lymph nodes in …
imaging (DWI) was evaluated as a potential tool for characterization of pelvic lymph nodes in …